Reperio, an UMCG spin-off company founded by NextGenVis fellow Alessandro Grillini, raised its first major investment. The company aims to accelerate the diagnostic process for glaucoma and neurodegenerative diseases using eye-tracking technology and analyses developed by Alessandro and colleagues.